Parker Waichman LLP

Multaq Patients Had Double Death Risk in Halted Trial

A study has found that patients taking Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to the study. According to a report from Bloomberg News, the findings come from a Multaq trial […]

A study has found that patients taking <"https://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to the study.

According to a report from Bloomberg News, the findings come from a Multaq trial of 3,236 patients that was halted in July because of the increased risk of death, heart attack and stroke. The trial, known as PALLAS, was a blow to Sanofi, the maker of the drug, and health care practitioners who had hoped Multaq would be a safe alternative to ather atrial fibrillation drugs.

“We have had a healthy suspicion of anti-arrhythmic drugs for many years, but we had thought this drug didn’t have the same risks,” lead researcher Stuart Connolly, from the Population Health Research Institute in Hamilton, Ontario, told Bloomberg in a telephone interview. “We are now getting the message that this drug has the potential to harm as well,” he said. “It seems this drug acts very differently depending on which type of patient receives it.”

The Multaq study, which was funded by Sanofi and published in the New England Journal of Medicine, was presented yesterday at the American Heart Association’s annual meeting in Orlando, Florida. According to Bloomberg, 21 Multaq patients died during the trial, compared to 10 among those getting placebo.

The U.S. Food and Drug Administration (FDA) is currently conducting a review of the safety of Multaq, but has not yet reached a decision regarding possible restrictions on the drug. In January, the FDA announced that the U.S. label for Multaq had been updated, following reports of liver damage, including severe liver failure, associated with the drug. The halt of the PALLAS study prompted the FDA to announce in July that it was expanding its review of Multaq, and the agency recommended that people taking Multaq speak with their physicians about the need to continue taking it. The FDA also reminded physicians that Multaq should not be prescribed to people with permanent atrial fibrillation.

In September, a committee of the European Medicines Agency (EMA) said Multaq shouldn’t be used in most people with permanent atrial fibrillation, but left it on the market for some patients with a more intermittent form of the disease. However, the agency also cautioned doctors to consider other atrial fibrillation treatments before they prescribe Multaq.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
PW’s nurse Joanne has been very attentive and supporting since my case has been initiated.
Tiff K
5 years ago
5 Star Reviews 150
I thank parker and waichman team for work so hard on my case Joonho hong, Josephine Burgess,Juila,joanne Stevens THANK YOU FOR A GREAT JOB IF I NEED ANOTHER TEAM IT WILL BE PARKER WAICHMAN HAPPY SUMMER
BRYANT LEE
5 years ago
5 Star Reviews 150
I have to admit I've been dealing with lots of professional people in my lifetime and Tina Morace has to be up there as a number one candidate. she was very attentive, caring, and on top of her game. because of her amazing work I will definitely recommend Parker Waichman to my family, friends and colleagues. Thank you Tina!! Great Job!!
Casimiro Cuevas
2 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038